Monitor the filing of the Form F-4 registration statement for key financial details on HCC Healthcare and the timeline for shareholder votes. The $500 million valuation and $10.00 implied per-share value set a floor for the combined entity, but shareholder redemptions from RFAM's trust account could reduce available cash. Watch for any competing proposals or regulatory delays, as the 270-day outside date provides a long tail.
Price Chart
Executive Summary
RF Acquisition Corp III (RFAM) announced a definitive Business Combination Agreement with HCC Healthcare Pte. Ltd., a Singapore-based private healthcare company. The deal values HCC Healthcare at a $500 million total equity value on a fully-diluted basis, with each HCC share valued at $10.00 post-recapitalization. RFAM shareholders will have their shares converted into HCC shares on a one-for-one basis, and the combined company will seek listing on Nasdaq or NYSE.
Key Financial Metrics
Key Facts
- Business Combination Agreement signed July 9, 2026 between RF Acquisition Corp III (RFAM) and HCC Healthcare Pte. Ltd.
- HCC Healthcare valued at $500 million total equity value on a fully-diluted basis, with each HCC ordinary share valued at $10.00 post-recapitalization.
- Each outstanding RFAM ordinary share will convert into one newly issued HCC ordinary share.
- Each RFAM right will convert into one-tenth of one HCC ordinary share.
- Closing subject to RFAM and HCC shareholder approvals, SEC registration statement effectiveness, and Nasdaq/NYSE listing approval.
- Founder (Alfa 30 Limited) and certain HCC shareholders entered into voting support and lock-up agreements for six months post-closing.
- RFAM will file a Form F-4 registration statement with the SEC as a proxy statement/prospectus for shareholder vote.
- The Business Combination Agreement has a 270-day outside closing date from signing.
- RFAM seeks to have the combined company's shares listed on Nasdaq or NYSE.
- No PIPE investment or additional financing mentioned in the filing.
Financial Impact
HCC Healthcare valued at $500 million total equity value on a fully-diluted basis at $10.00 per share. No additional financing or PIPE disclosed. Actual closing proceeds depend on RFAM shareholder redemptions from the trust account.
Risk Factors
- Shareholder redemptions could reduce trust account proceeds significantly, impacting post-merger cash position.
- Failure to obtain regulatory approvals or Nasdaq/NYSE listing approval could derail the transaction.
- The 270-day outside closing date introduces execution risk and potential for termination if conditions are not met.
- HCC Healthcare's unaudited financial statements and lack of PCAOB-audited financials increase uncertainty until the Form F-4 is filed.
- No PIPE or committed financing disclosed, creating reliance on trust account funds.
- Conversion of RFAM rights into one-tenth of an HCC share creates dilution for rights holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001829126-26-007473 |
| Document: 0001829126-26-007473-index.html | 0001829126-26-007473 |
| Document: 0001829126-26-007473.txt | 0001829126-26-007473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 15w ago | 425 | $9.92 $9.91 | ▼ −0.10% | ▼ −2.53% | $9.99 (+0.71%) |
Feb 24, 2026 35w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers